Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma

Background: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels repre...

Full description

Bibliographic Details
Main Authors: Creaney, J., Olsen, N., Brims, Fraser, Dick, I., Musk, A., De Klerk, N., Skates, S., Robinson, B.
Format: Journal Article
Published: American Association for Cancer Research Inc 2010
Online Access:http://hdl.handle.net/20.500.11937/9994
_version_ 1848746135652401152
author Creaney, J.
Olsen, N.
Brims, Fraser
Dick, I.
Musk, A.
De Klerk, N.
Skates, S.
Robinson, B.
author_facet Creaney, J.
Olsen, N.
Brims, Fraser
Dick, I.
Musk, A.
De Klerk, N.
Skates, S.
Robinson, B.
author_sort Creaney, J.
building Curtin Institutional Repository
collection Online Access
description Background: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals. In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma. Methods: Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestosexposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified. Serum mesothelin concentrations were determined using the MESOMARK assay. Results: Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001). There was no correlation between mesothelin concentration and cumulative asbestos exposure. Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people. Using an increase above the 95% confidence interval of the mean of a given individual's longitudinal mesothelin results, 33 of 82 individuals had increasing mesothelin levels before diagnosis. Conclusion: In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group. Impact: Future studies examining a combination of biomarkers could improve sensitivity of screening. ©2010 AACR.
first_indexed 2025-11-14T06:28:27Z
format Journal Article
id curtin-20.500.11937-9994
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:28:27Z
publishDate 2010
publisher American Association for Cancer Research Inc
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-99942017-09-13T14:55:43Z Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma Creaney, J. Olsen, N. Brims, Fraser Dick, I. Musk, A. De Klerk, N. Skates, S. Robinson, B. Background: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals. In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma. Methods: Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestosexposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified. Serum mesothelin concentrations were determined using the MESOMARK assay. Results: Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001). There was no correlation between mesothelin concentration and cumulative asbestos exposure. Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people. Using an increase above the 95% confidence interval of the mean of a given individual's longitudinal mesothelin results, 33 of 82 individuals had increasing mesothelin levels before diagnosis. Conclusion: In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group. Impact: Future studies examining a combination of biomarkers could improve sensitivity of screening. ©2010 AACR. 2010 Journal Article http://hdl.handle.net/20.500.11937/9994 10.1158/1055-9965.EPI-10-0346 American Association for Cancer Research Inc unknown
spellingShingle Creaney, J.
Olsen, N.
Brims, Fraser
Dick, I.
Musk, A.
De Klerk, N.
Skates, S.
Robinson, B.
Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
title Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
title_full Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
title_fullStr Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
title_full_unstemmed Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
title_short Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
title_sort serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma
url http://hdl.handle.net/20.500.11937/9994